Body weight reduction and pharmacological therapy for diabetes such as glucagon-like peptide-1 (GLP-1) agonists and sodium glucose cotransporter 2 (SGLT2) inhibitors ameliorate pathological findings of NAFLD [19]. This evidence concerns the gene GCG and metabolic dysfunction-associated steatotic liver disease.